- In January 2025, Novartis launched a new indication for canakinumab targeting refractory adult-onset Still's Disease, following robust Phase III clinical trial results. The data demonstrated a significant reduction in disease flares and improved long-term remission rates, prompting regulatory approvals in the U.S. and select European markets. This move strengthens Novartis’ biologics portfolio and expands therapeutic options for patients with difficult-to-treat systemic inflammation.
- In September 2024, Regeneron expanded its IL-1 research program to include systemic juvenile idiopathic arthritis (sJIA), aiming to target Still’s-like pathology at earlier stages of disease progression. The initiative focuses on developing next-generation IL-1 inhibitors with enhanced safety profiles and broader pediatric indications, supporting the company’s long-term vision in rare auto-inflammatory conditions.
- In July 2024, Sobi collaborated with the European Paediatric Rheumatology Society (PReS) to conduct a real-world observational study assessing the safety, tolerability, and clinical outcomes of anakinra in pediatric Still’s Disease patients. The study spans over 10 countries and involves over 400 children, marking one of the most comprehensive real-world evidence efforts for IL-1 inhibitors in this indication.
- In March 2024, Sanofi received orphan drug designation in Japan for its IL-6 inhibitor sarilumab for the treatment of systemic juvenile idiopathic arthritis with features of Still's Disease. This regulatory milestone supports Sanofi’s strategy to expand sarilumab into pediatric autoimmune conditions and strengthens its position in the Asian immunology market.
